ReviewJHEP reports : innovation in hepatology2019
Non-alcoholic fatty liver disease in lean individuals.
Review in JHEP reports : innovation in hepatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 98 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
98 citing papers in PubMed, 4 syntheses or guidelines pooled it, 171 citations in OpenAlex.
- Therapeutic Effects of Glucagon-like Peptide-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: A Systematic Review.International journal of molecular sciences · 2026Pooled it
- Probiotics as emerging adjuncts in metabolic associated fatty liver disease therapy-a systemic review.BMC gastroenterology · 2026Pooled it
- Complex impacts of gallstone disease on metabolic syndrome and nonalcoholic fatty liver disease.Frontiers in endocrinology · 2022Pooled it
- Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review.Diabetes, obesity & metabolism · 2021Pooled it
- Culturally adapted hypocaloric diet improves hepatic steatosis, inflammatory and oxidative biomarkers in Egyptian MASLD patients: a single-arm interventional study.Lipids in health and disease · 2025Trial
- A Distinctive NAFLD Signature in Adipose Tissue from Women with Severe Obesity.International journal of molecular sciences · 2021Trial
- Molecular mechanisms and pathogenesis of MASH.Nature · 2026Review
- Multidimensional Classification of Insulin Resistance (MCIR) Focused on Therapeutic Targets and Interventions-A Comprehensive Review.International journal of molecular sciences · 2026Review
- Cardioprotective Effects of 1,3 Butanediol in MASLD via Reversal of Cardiac Lipid Accumulation and Suppression of Cardiac Fibrosis.International journal of molecular sciences · 2026Article
- Liver steatosis and fibrosis in acromegaly patients with active and controlled disease: a scoping review.Journal of endocrinological investigation · 2026Review
- Prevalence and Correlates of Steatotic Liver Disease Among People With HIV in Uganda.Open forum infectious diseases · 2026Article
- Interrelationships Between Key Cardiovascular Risk Factors, Chronic Kidney Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease.Current cardiology reports · 2026Review
- Deletion of hepatic growth hormone receptor contributes to the pathogenesis of lean MAFLD by elevating CD36.Life metabolism · 2026Article
- Dysregulated high-density lipoprotein and low-density lipoprotein subfractions increase metabolic dysfunction-associated steatotic liver disease risk: a study of patients across body mass index categories.Frontiers in nutrition · 2026Article
- Serum Extracellular Vesicles as Pathogenetic Signals in Obese and Lean Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease.Metabolites · 2025Article
- Endoplasmic reticulum stress at the forefront of fatty liver diseases and cancer.Pharmacological reviews · 2025Review
- Article
- Malnutrition induces steatohepatitis by impairing hepatic lipid metabolism, mitochondrial function and the gut-liver axis.Journal of physiology and biochemistry · 2025Article
- Article
- Association of lean metabolic dysfunction-associated steatotic liver disease with carotid plaque progression in patients with type 2 diabetes mellitus.Journal of diabetes investigation · 2025Article
38 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-alcoholic fatty liver disease (NAFLD) is a major cause of chronic liver disease, encompassing a spectrum from non-alcoholic fatty liver to non-alcoholic steatohepatitis, which can progress to cirrhosis. It has recently been recognised that NAFLD also occurs in individuals who are not obese, especially in Asian populations. In these patients, NAFLD manifests at lower overall body mass index thresholds in the presence of increased visceral adipose tissue. Currently, the principles of clinical management are similar to those in obese individuals, although, in specific regions and clinical situations, unique aetiologies of NAFLD must be treated specifically.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.